Currently there is a phase I clinical trial on-going evaluating WNT inhibitors in patients with malignancies dependent on WNT ligands and includes patients with RNF43-mutated pancreatic cancer [113]. The gene discussed is RNF43; the disease is familial pancreatic carcinoma.